Targeted Therapies Broad Potential
We are focused on developing targeted therapies for
immune-inflammatory diseases
Our lead candidate VB-601 has potential to be broadly applicable across both prevalent & rare inflammatory indications.
Our expertise in human biology led to the development of our proprietary monocyte targeting technology (MTT), which is designed in a specific way to limit chronic inflammation.
